Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

In this study, researchers identified 173 differentially expressed genes in alopecia areata patients linked to immune and hair follicle pathways, constructed a regulatory network involving mRNA, miRNA, and lncRNA, and highlighted CD8A and FOXD2-AS1 as potential diagnostic markers and therapeutic targets.

This study constructed a model using serum levels of BMP2, CD8A, PRF1, and XCL1 as a non-invasive biomarker to accurately predict recurrence in patients with alopecia areata.

This study suggests that novel diagnostic, preventive, and treatment approaches for autoimmune diseases like alopecia areata may be developed by identifying hub genes, and highlights the usefulness of machine learning and bioinformatics in finding new disease biomarkers.